1. Home
  2. CYCU vs CALC Comparison

CYCU vs CALC Comparison

Compare CYCU & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cycurion Inc.

CYCU

Cycurion Inc.

HOLD

Current Price

$1.07

Market Cap

7.8M

Sector

N/A

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.57

Market Cap

9.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYCU
CALC
Founded
2017
2011
Country
United States
United States
Employees
N/A
16
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
9.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CYCU
CALC
Price
$1.07
$0.57
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$7.00
$10.00
AVG Volume (30 Days)
374.1K
283.5K
Earning Date
04-01-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.46
52 Week High
$7.13
$7.20

Technical Indicators

Market Signals
Indicator
CYCU
CALC
Relative Strength Index (RSI) 37.34 34.86
Support Level $0.25 $0.49
Resistance Level $2.91 $0.79
Average True Range (ATR) 0.16 0.08
MACD 0.00 0.04
Stochastic Oscillator 47.80 16.43

Price Performance

Historical Comparison
CYCU
CALC

About CYCU Cycurion Inc.

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: